

INDEVUS PHARMACEUTICALS INC

Form 8-K

June 10, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

May 28, 2004

Indevus Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

000-18728
(Commission File Number)

04-3047911
(IRS Employer

Identification Number)

Edgar Filing: INDEVUS PHARMACEUTICALS INC - Form 8-K

One Ledgesmont Center

99 Hayden Avenue

Lexington, Ma 02421-7966

(Address of principal executive offices)

Registrant's telephone number, including area code:

(781-861-8444)

Item 5. Other Events and Regulation FD Disclosure.

On May 28, 2004, Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SANCTURA (trospium chloride tablets). This Press Release is attached hereto as Exhibit 99.1.

On June 2, 2004, Indevus Pharmaceuticals, Inc., issued a press release announcing that it has received a milestone payment of \$120 million from PLIVA d.d. for the approval of SANCTURA by the U.S. Food and Drug Administration. This Press Release is attached hereto as Exhibit 99.2.

Item 7. Financial Statements and Exhibits.

99.1 Press Release of the Registrant dated May 28, 2004; and

99.2 Press Release of the Registrant dated June 2, 2004.

The exhibits hereto contain forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA; the early stage of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA; risks associated with contractual agreements; dependence on third parties for manufacturing and marketing; competition; need for additional funds and corporate partners, including for the commercialization of SANCTURA and for the development of our other products; failure to acquire and develop additional product candidates; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux-related litigation; limited patent and proprietary rights; dependence on market exclusivity; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; and other risks.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INDEVUS PHARMACEUTICALS, INC.

Dated: June 10, 2004

By: /s/ Glenn L. Cooper, M.D.

Glenn L. Cooper, M.D.
President, Chief Executive Officer and Chairman